Comments
Vivimed Labs has received establishment inspection report (EIR) from the US health regulator for its Mexico manufacturing facility.
“The company’s API manufacturing facility located in Cuernavaca, Mexico was recently inspected by the United States Food and Drug Administration (USFDA) in compliance with its requirements,” Vivimed Labs said in a BSE filing today.
“The inspection was successful and the company obtained EIR. This was a routine inspection by the USFDA,” it added.
Shares of Vivimed Labs were trading at Rs 40 per scrip on BSE, up 2.17 per cent, from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.